Ohio State's novel DHODH inhibitor enters first human trials - News-Medical

A new DHODH inhibitor, HOSU-53, developed at The Ohio State University, will undergo a clinical trial for cancer treatment, targeting key cellular metabolic processes essential for cancer growth.